Latest Pharma Insights
Chairmen Of House Committees With FDA Oversight In Opposite Corners On Lawful Hemp
Delaying or altogether eliminating limits on all THCs in lawful hemp Congress approved in 2025 could come down to either House Appropriations, chaired by a proponent for lower limits, or Energy and Commerce, chaired by a supporter for eliminating lower limits.
HBW Insight - March 10, 2026
Delaying or altogether eliminating limits on all THCs in lawful hemp Congress approved in 2025 could come down to either House Appropriations, chaired by a proponent for lower limits, or Energy and Commerce, chaired by a supporter for eliminating lower limits.
HBW Insight - March 10, 2026
Xenon’s Seizure Drug Data Make A Strong Case For Clinical Use
Phase III results for azetukalner in focal onset seizures bested the impressive placebo-adjusted Phase IIb data for the first-in-class drug, which Xenon designed to overcome challenges of other anti-seizure medications.
Scrip - March 9, 2026
Phase III results for azetukalner in focal onset seizures bested the impressive placebo-adjusted Phase IIb data for the first-in-class drug, which Xenon designed to overcome challenges of other anti-seizure medications.
Scrip - March 9, 2026
Alfasigma Acquires Near-To-Market PBC Drug From GSK
Deal Snapshot: The Italian specialty pharma is gaining linerixibat, slated for US approval on March 24 and potentially replacing Ocaliva, which was pulled from the market last September.
Scrip - March 9, 2026
Deal Snapshot: The Italian specialty pharma is gaining linerixibat, slated for US approval on March 24 and potentially replacing Ocaliva, which was pulled from the market last September.
Scrip - March 9, 2026
BMS’s Mezigdomide Scores In Second-Line Myeloma
The CELMoD combined with Kyprolis/dexamethasone showed superior PFS, bringing another combination to the second-line disease setting.
Scrip - March 9, 2026
The CELMoD combined with Kyprolis/dexamethasone showed superior PFS, bringing another combination to the second-line disease setting.
Scrip - March 9, 2026
Pfizer Tries Again In Atopic Dermatitis, This Time With A Trispecific
The company is advancing tilrekimig into Phase III development based on positive Phase II efficacy data that suggest a potential improvement over biologic standard of care Dupixent.
Scrip - March 9, 2026
The company is advancing tilrekimig into Phase III development based on positive Phase II efficacy data that suggest a potential improvement over biologic standard of care Dupixent.
Scrip - March 9, 2026
UniQure Leads Biotechs Heartened By Prasad’s Second FDA Exit
Shares have surged in companies who have fallen foul of Prasad’s stricter approach, but it is not clear whether a future successor will continue or reverse his policies.
Scrip - March 9, 2026
Shares have surged in companies who have fallen foul of Prasad’s stricter approach, but it is not clear whether a future successor will continue or reverse his policies.
Scrip - March 9, 2026
Lundbeck Shines Light On Amlenetug
The Phase III anti-alpha-synuclein antibody has the potential to become a first-in-class therapy for multiple system atrophy.
Scrip - March 9, 2026
The Phase III anti-alpha-synuclein antibody has the potential to become a first-in-class therapy for multiple system atrophy.
Scrip - March 9, 2026
Ipsen To Pull Tazverik Following Safety Concerns
Ipsen will withdraw its anticancer, Tazverik, worldwide after its SYMPHONY?1 trial revealed cases of secondary hematologic malignancy.
Scrip - March 9, 2026
Ipsen will withdraw its anticancer, Tazverik, worldwide after its SYMPHONY?1 trial revealed cases of secondary hematologic malignancy.
Scrip - March 9, 2026
Roche’s Predicted Mega-Blockbuster Giredestrant Faces Phase III Setback
Roche’s Phase III persevERA trial of giredestrant plus palbociclib in first-line ER-positive advanced breast cancer has missed its progression-free survival endpoint.
Scrip - March 9, 2026
Roche’s Phase III persevERA trial of giredestrant plus palbociclib in first-line ER-positive advanced breast cancer has missed its progression-free survival endpoint.
Scrip - March 9, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: smaller companies consider European expansion under MFN; Pfizer CEO on FDA vaccine decisions; what does big pharma want from CRDMOs in AI age; neuroscience funding poised for comeback; and UCB’s big China deal.
Scrip - March 9, 2026
In this week's episode: smaller companies consider European expansion under MFN; Pfizer CEO on FDA vaccine decisions; what does big pharma want from CRDMOs in AI age; neuroscience funding poised for comeback; and UCB’s big China deal.
Scrip - March 9, 2026
Not Losing Heart: HeartBeam Wins FDA Approval Of Novel ECG Device After Appealing NSE Determination
HeartBeam’s CEO says the strength of clinical data convinced the US FDA to reverse course and grant clearance to his company’s innovative ECG device, which he says can assess arrhythmias at home with hospital accuracy.
Medtech Insight - March 9, 2026
HeartBeam’s CEO says the strength of clinical data convinced the US FDA to reverse course and grant clearance to his company’s innovative ECG device, which he says can assess arrhythmias at home with hospital accuracy.
Medtech Insight - March 9, 2026
MiniMed’s Nasdaq Debut Underwhelms Amid Market Jitters And Geopolitical Uncertainty
A turbulent market backdrop, geopolitical shock following the US and Israel striking Iran days before pricing, and a limited public float is likely to have weighed on investor appetite.
Medtech Insight - March 9, 2026
A turbulent market backdrop, geopolitical shock following the US and Israel striking Iran days before pricing, and a limited public float is likely to have weighed on investor appetite.
Medtech Insight - March 9, 2026
Latest Tally Shows 1,821 FDA-Cleared Digital Health Tools
Recently published lists show that the US Food and Drug Administration had cleared almost 2,000 digital health tools by the end of 2025. Of these, well over half – 1,104 – were radiology devices incorporating AI. Find a full breakdown in these tables.
Medtech Insight - March 9, 2026
Recently published lists show that the US Food and Drug Administration had cleared almost 2,000 digital health tools by the end of 2025. Of these, well over half – 1,104 – were radiology devices incorporating AI. Find a full breakdown in these tables.
Medtech Insight - March 9, 2026
Deals Shaping The Medtech And Diagnostics Industries, February 2026
An interactive look at medtech and diagnostics deals made during February 2026. Data courtesy of Biomedtracker.
Medtech Insight - March 9, 2026
An interactive look at medtech and diagnostics deals made during February 2026. Data courtesy of Biomedtracker.
Medtech Insight - March 9, 2026
Chairmen Of House Committees With FDA Oversight In Opposite Corners On Lawful Hemp
Delaying or altogether eliminating limits on all THCs in lawful hemp Congress approved in 2025 could come down to either House Appropriations, chaired by a proponent for lower limits, or Energy and Commerce, chaired by a supporter for eliminating lower limits.
HBW Insight - March 10, 2026
Delaying or altogether eliminating limits on all THCs in lawful hemp Congress approved in 2025 could come down to either House Appropriations, chaired by a proponent for lower limits, or Energy and Commerce, chaired by a supporter for eliminating lower limits.
HBW Insight - March 10, 2026
GDUFA IV: Sponsors May See ANDA Prioritization If Some Production Aspects Onshored
The FDA offered to relax the onshoring criteria to receive a priority ANDA review in GDUFA IV, but could drop another America First proposal.
Generics Bulletin - March 9, 2026
The FDA offered to relax the onshoring criteria to receive a priority ANDA review in GDUFA IV, but could drop another America First proposal.
Generics Bulletin - March 9, 2026
Formycon Flags Missed Guidance Ahead Of The FY2025 Results Report
Deal after deal, Formycon was inching toward closing the gap in its annual guidance. Still, it was not enough to meet the goal, as the German biosimilars developer’s preliminary financial report reveals.
Generics Bulletin - March 9, 2026
Deal after deal, Formycon was inching toward closing the gap in its annual guidance. Still, it was not enough to meet the goal, as the German biosimilars developer’s preliminary financial report reveals.
Generics Bulletin - March 9, 2026
EMS To Bolster Brazilian Generics Position With $500m+ Medley Buyout
Brazil’s EMS has agreed to acquire Sanofi’s Medley generics business in a deal aimed at strengthening its position in the country’s off-patent medicines market, with the combined platform potentially reaching about 32% share pending regulatory approval.
Generics Bulletin - March 9, 2026
Brazil’s EMS has agreed to acquire Sanofi’s Medley generics business in a deal aimed at strengthening its position in the country’s off-patent medicines market, with the combined platform potentially reaching about 32% share pending regulatory approval.
Generics Bulletin - March 9, 2026
Amphastar’s Secretive Inhaler Candidate Revealed As Atrovent HFA Generic After FDA Nod
Previously known only as AMP-007, the generic Atrovent HFA inhaler is now set for a Q2 launch with six months of exclusivity.
Generics Bulletin - March 9, 2026
Previously known only as AMP-007, the generic Atrovent HFA inhaler is now set for a Q2 launch with six months of exclusivity.
Generics Bulletin - March 9, 2026
Merck’s Oncology Portfolio Strategy Beyond Keytruda
Merck's post-Keytruda oncology strategy rests on three pillars – immune deepening, tissue targeting and tumor-intrinsic mechanisms – anchored by patient selection, AI-accelerated discovery and a KRAS bet that could define its next era.
In Vivo - March 9, 2026
Merck's post-Keytruda oncology strategy rests on three pillars – immune deepening, tissue targeting and tumor-intrinsic mechanisms – anchored by patient selection, AI-accelerated discovery and a KRAS bet that could define its next era.
In Vivo - March 9, 2026
Biotech Britain Vs. The World
Industry leaders share how Britain can strengthen its biotech ecosystem, from capital and regulation to talent and ambition, and what the sector could look like by 2030.
In Vivo - March 9, 2026
Industry leaders share how Britain can strengthen its biotech ecosystem, from capital and regulation to talent and ambition, and what the sector could look like by 2030.
In Vivo - March 9, 2026
Deals Shaping The Industry, February 2026
An interactive look at pharma, medtech and diagnostics deals made during February 2026. Data courtesy of Biomedtracker.
In Vivo - March 9, 2026
An interactive look at pharma, medtech and diagnostics deals made during February 2026. Data courtesy of Biomedtracker.
In Vivo - March 9, 2026